During the pre-RA period the autoantibody responses, including ACPA, is increased in titers and spreads in epitope specificity [1] and that antibodies to cartilage can be measured around clinical onset [2-4], where one of the autoantibody targets is collagen type II (CII). Here, PRTN3 is linked to rheumatoid arthritis.